Connect Biopharma Holdings Ltd Cash Flow Statement
CNTB|2 years of annual SEC 10-K data (FY2024-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$51M
FY2025
Free Cash Flow
-$52M
FY2025
Capital Expenditures
$434,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Connect Biopharma Holdings Ltd used $51M in operating cash flow and negative free cash flow of $52M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 |
|---|---|---|
| Net Income | -$55.5M | -$62.1M |
| Depreciation & Amortization | $704.0K | $720.0K |
| Operating Cash Flow | -$51.2M | -$47.7M |
| Capital Expenditures | $434.0K | $81.0K |
| Free Cash Flow | -$51.6M | -$47.8M |
| FCF Margin | -80687.5% | - |